Table 1.
Demographics and Outcomes of Participants With Adjudicated Episodes of Pneumonia
Demographics and Outcomes of Study Participants | |
---|---|
Variable | No. (%) |
Age, median [IQR], y | 62 [51–72] |
Gender | |
Male | 349 (59.0) |
Female | 244 (41.1) |
Ethnicity | |
Hispanic | 124 (20.9) |
Not Hispanic or Latino | 446 (75.2) |
Not answered | 23 (3.9) |
Race (self-identified) | |
African American or Black | 119 (20.1) |
American Indian or Alaska Native or Asian Indian | 6 (1.0) |
Asian | 17 (2.9) |
Native Hawaiian or other Pacific Islander | 2 (0.3) |
White | 351 (59.2) |
None of the above or patient declined to answer | 98 (16.5) |
Pneumonia category for initial episode (n = 593) | |
Clinical CAP | 132 (22.3) |
Clinical HAP | 205 (34.6) |
Clinical VAP | 162 (27.3) |
Nonpneumonia episode (37 single adjudicator, 57 adjudicated)a | 94 (15.9) |
Pneumonia etiology (n = 593) | |
Viral only | 153 (25.8) |
Bacterial only | 150 (25.3) |
Viral/bacterial coinfection | 87 (14.7) |
Indeterminate | 3 (0.1) |
Culture-negative | 106 (17.9) |
Nonpneumonia | 94 (15.9) |
No. of episodes (n = 593) | |
Multiple episodes | 120 (20.2) |
Single episode | 473 (79.8) |
Comorbid conditions | |
Cerebrovascular disease | 124 (20.9) |
Congestive heart failure | 173 (29.2) |
Malignancy | 200 (33.7) |
Diabetes | 213 (35.9) |
Chronic pulmonary disease | 212 (35.7) |
Liver disease | 155 (25.2) |
Renal disease | 159 (26.8) |
Hospitalization | |
Hospital length of stay, median [IQR] | 23 [13–37] |
ICU length of stay, median [IQR] | 14 [6–25] |
Patients with day 7–8 adjudicationa | 257 (60.0) |
Hospital mortality | 189 (37.5) |
Abbreviations: CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia; ICU, intensive care unit; IQR, interquartile range; VAP, ventilator-associated pneumonia.
Patients with viral-only pneumonia, nonpneumonia, and those who were deceased, discharged, or transferred to another facility before day 7–8 did not have a day 7–8 adjudication. The etiologies of pneumonia and of nonpneumonia respiratory failure are listed in Supplementary Table 1.